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ABSTRACT
This study compares the diagnostic performance of urine and serum multiple biomarkers for early diagnosis of ovarian 
cancer. The sample population includes 119 benign and 101 ovarian cancer patients. The marker combinations used 
to compare performance include 16 markers whose concentration  values were obtained  using the Luminex assay. In 
order to identify an optimal marker combination that could classify ovarian cancer and benign patients, the area under 
the curve (AUC) is used to evaluate 2-, 3-, and 4-marker  combinations and the classification is performed by using 
logistic regression. In the case of urine samples, the best AUC values are 87.89% for the 2 protein markers combination, 
90.22% for the 3 markers combination, and 92.43% for the 4 marker combination. In contrast, the best AUC values 
for serum sample are 92.4% for the 2 marker combination, 93.63% for the 3 marker combination and 94.63% for the 
4 marker combination. This study confirmed that combining multiple biomarkers could improve diagnostic accuracy. 
Even though  the urine sample shows relatively lower performance than serum, urine could be utilized more widely for 
its simple usability.
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ABSTRAK
Kajian ini membandingkan prestasi diagnostik air kencing dan beberapa penanda biologi serum untuk diagnosis awal 
kanser ovari. Gabungan penanda digunakan untuk membandingkan prestasi 16 penanda dan nilai kepekatan diperoleh 
dengan menggunakan logam penguji Luminex. Untuk menentukan gabungan penanda optimum yang boleh mengenal 
pasti kanser ovari dan pesakit biasa, luas di bawah lengkungan (AUC) digunakan untuk menilai kombinasi penanda 2-, 
3- dan 4-. Pengelasan dijalankan dengan menggunakan regresi logistik. Dalam kes sampel air kencing, nilai AUC yang 
terbaik adalah 87.89% untuk 2 kombinasi penanda protein, 90.22% untuk 3 kombinasi penanda dan 92.43% untuk 4 
kombinasi penanda. Sebaliknya, nilai AUC yang terbaik untuk sampel serum adalah 92.4% untuk 2 kombinasi penanda, 
93.63% untuk 3 kombinasi penanda dan 94.63% untuk 4 kombinasi penanda. Kajian ini mengesahkan bahawa gabungan 
beberapa penanda biologi boleh meningkatkan ketepatan diagnostik. Walaupun sampel air kencing menunjukkan prestasi 
yang agak rendah daripada serum, air kencing boleh digunakan dengan lebih meluas untuk kebolehgunaan yang mudah.
Kata kunci: Air kencing; kanser ovari; penanda biologi; serum
INTRODUCTION
Ovarian cancer is a malignant tumor with the highest 
incidence in women between the ages of 50 and 70 years. 
Annually, 1,000-1,200 new cases of ovarian cancer were 
diagnosed and it is the second most common gynecologic 
cancer after cervical cancer. For all ovarian cancers, the 
5-year survival rate is 44% and that of early-diagnosed 
epithelial ovarian cancer is 60−90%; however, when 
diagnosed after stage 3, the 5-year survival rate drops to 
40% (American Cancer Society) (Table 1).
 Clinical diagnosis of ovarian cancer requires surgical 
biopsy; however, for lesions in which ovarian cancer 
is suspected before surgery, various clinical tests must 
be carried out to check the stage of progression and 
metastasis of cancer organs. At the first diagnosis stage, 
vaginal ultrasound to check the outward shape and size 
of the tumor and serum CA-125 testing having suitable 
sensitivity for ovarian cancer detection were conducted 
(Nolen et al. 2009). As an ovarian cancer diagnostic 
method, pelvic examination helps clinicians assess the 
size, appearance and mobility of the ovaries; if they 
are hard with an irregular surface, whether the tumor is 
suspicious for malignant ovarian cancer can be determined. 
However, the sensitivity of pelvic examination for the 
diagnosis of ovarian cancer is quite low at 30% (Nolen et 
al. 2009). Therefore, ultrasound examination, developed 
by technological advances after the 1970s, has been used 
for ovarian cancer screening. Among many ultrasound 
examinations, transvaginal ultrasound approaches organs 
in the abdominal cavity with good resolution to effectively 
visualize the size and shape of ovaries and to check 
the presence of ovarian tumors, but it was difficult to 
distinguish between normal and abnormal states with this 
technique. 
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 The CA-125 test assesses serum CA-125 glycoprotein 
concentrations was used to diagnose epithelial ovarian 
tumors. Of the biomarkers used for ovarian cancer 
detection, CA-125 is the most commonly clinically used 
biomarker and 85% of the patients with epithelial ovarian 
cancer show positive reaction to the marker, with 35 U/
mL of the cut-off point for positive reaction. In the case of 
early ovarian cancer (stages 1 and 2), only 50-60% show 
positive reaction and for late-stage ovarian cancer (stages 
3 and 4), more than 90% of patients show positive reaction 
(American Cancer Society). However, CA-125 may also 
increase during endometriosis, regular menstruation, 
ovarian cysts and pregnancy; therefore, this test alone 
cannot be used to confirm the diagnosis of the cancer 
(Nolen et al. 2009). An early stage ovarian cancer patient 
does not show specific observable symptoms; expensive 
and unnecessary surgical examinations could be required. 
Epithelial cancers, which account for over 90% of all 
ovarian cancers, are usually discovered later than stage 
3; therefore, the need for a diagnostic examination that 
could discover ovarian cancer at early stages has become 
increasingly important (Nolen et al. 2009).
 For diagnosis of early-stage cancer, a single marker 
cannot provide sufficient sensitivity and specificity; 
therefore, a diverse combination of biomarkers is needed 
for early diagnosis of ovarian cancer (Pepe et al. 2006; 
Yukovetsky et al. 2013). An examination method using 
biomarkers, involving methods using serum or urine, is 
a comparatively simpler and less expensive method than 
other diagnostic tests used for early diagnosis of cancer 
(Feng et al. 2006).
 A biomarker refers to a marker that can accurately 
determine whether an organism is pathologically normal 
or abnormal and how much the organism reacts to a 
specific drug. Specifically, a biomarker can determine 
the pathologic status of a disease and predict the extent 
of an organism’s reaction when a specific drug is used 
to treat the disease. An ideal tumor marker is a protein 
detected in fragments from the patient’s urine and serum, 
which were not found in normal individuals (Chatterjee 
& Zetter 2005; Hellstrom et al. 2010; Moore et al. 2008). 
The United States Food and Drug Administration (FDA) 
with the goal of cancer diagnosis, have approved the use 
of tumor-related biomarkers. In 2007, the FDA published 
regulations and guidelines regarding the use of ‘in vitro 
diagnostic multivariate index assays’ (IVDMIAs). The FDA 
defines an IVDMIA as a combined device that combines 
biomarker values to create a specific output consisting of 
a classification, score and index using analytic functions, 
with the overall goal of diagnosis, mitigation, treatment 
and prevention (Food and Drug Administration). 
Normally, we do not have enough biomarkers showing 
almost 100% specificity to t specific disease. To resolve 
this problem, the IVDMIA could improve the diagnostic 
accuracy by combining multiple biomarkers and by 
statistically analyzing the numbers related to the markers. 
Unlike a single biomarker presupposing only one single 
value, the IVDMIA combines multiple values from multiple 
biomarkers which complement each other. Therefore, it 
yields better results than biomarkers used individually 
(Zhang 2012).
 Studies on biomarkers for diagnosis of ovarian 
cancers normally use serum biomarkers instead of urine. 
But urine biomarkers are easily handled clinically and are 
also used for a completely non-surgical tumor detection 
method that can detect cancer patients earlier among 
patients with positive reaction (Kim et al. 2010; Nolen 
& Lokshin 2012; Petri et al. 2010).
 Petri et al. (2010) compared the receiver-operating 
characteristic (ROC) area under the curve (AUC) values 
between serum and urine samples in the same patient 
group, showing little ROC values different between the 
urine biomarker at 84% and the serum biomarker at 83%. 
The majority of the women with clinical signs of ovarian 
cancer have benign conditions; therefore, a method capable 
of differentiating between benign conditions and ovarian 
cancer would be beneficial (Amonkar et al. 2009).
 The present study aimed to evaluate the diagnostic 
performance between urine and serum biomarkers, 
which classify the benign patients and the ovarian cancer 
patients. A total of 16 similar urine and serum biomarkers 
were used to construct 2-4-biomarker combinations to 
evaluate the AUC of the ROC and diagnostic performance 
of the optimal marker combination was assessed using 
logistic regression.
DATA COLLECTION
The sample population for urine biomarker evaluation 
consisted of 119 benign patients and 101 ovarian cancer 
patients and that for serum biomarker evaluation consisted 
of 119 benign and 101 ovarian cancer patients. Even though 
the numbers of urine and serum samples were the same, 
those samples are collected from different patients groups. 
This was due to the difficulty in simultaneously obtaining 
urine and serum biomarker samples from the same patient. 
TABLE 1. Relative 5-year ovarian cancer survival rates
Stage Ⅰ ⅠA ⅠB ⅠC Ⅱ ⅡA –
Relative 5-year survival rate 89% 94% 91% 80% 66% 76% –
Stage ⅡB ⅡC ⅡD ⅢA ⅢB ⅢC Ⅳ
Relative 5-year survival rate 67% 57% 34% 45% 39% 35% 18%
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In this study, 16 different urine and blood biomarkers were 
used. A total of 220 Korean women samples from the ASAN 
Medical Center (2010) were included in the study. Tables 2 
and 3 present information about the tested clinical samples.
 The urine and serum biomarker concentrations were 
assessed by using the Luminex (Nolen & Lokshin 2012) 
multiplex immunoassay method and an ovarian tumor-
specific biomarker immunoassay kit (Borgia et al. 2009). 
The analysis was conducted according to the protocol 
provided by Luminex and the samples were analyzed using 
the Bio-Plex suspension array system (Jung et al. 2009). 
The expression level of biomarkers was set as the medium 
fluorescence intensity produced from 50-100 microbeads 
per analyte per sample. The analyte concentration was 
assessed using Bio-Rad 5-parameter curve fitting at 
medium-level fluorescent intensity (Zhang 2012).
METHODS
In order to identify an accurate biomarker combination 
with a high diagnostic accuracy for ovarian cancer, the 
performance of urine and serum biomarker combinations 
was compared. To determine biomarker combinations 
that can best differentiate between the ovarian cancer and 
benign cases, the ability to differentiate between subsets 
of combined markers was assessed to find the optimal 
subset (Saeys et al. 2007). Sensitivity and specificity must 
both be evaluated to choose a model with appropriate 
differentiation performance. A standard method for 
harmonizing sensitivity and specificity includes calculating 
the AUC of the ROC (Pepe et al. 2006). This study used 
logistic regression to evaluate the AUC of the ROC and 
choose marker combinations with the highest values. 
 Logistic regression is a standard statistical algorithm 
used when samples are divided into 2 or more groups 
(multivariate data) and predicts a proper group in which 
individual observation will fall. The relationship between 
input patterns (independent variable) and resulting value 
(dependent variable) is quantified. If the probability of an 
event of independent variable is p, the odds value of this 
event is obtained and through logit transformation S curve 
is transformed linearly, showing the specific characteristic 
of the regression model. 
 . (1)
 In this case, xn is the independent variable and bn is the 
logistic regression value. The regression value is calculated 
using the Newton-Raphson method of repetitive analysis. 
Setting the value obtained from the regression model (1) 
as z, the probability P is calculated using (2).
 p =  (2)
 The cut-off value is applied to this probability to 
determine into which type it will fall (Kohavi 1995).
 The average AUC value was calculated by repeating 
5-fold cross validation 1000 times to choose the best urine 
and serum biomarker combination. Lastly, the combination 
with the highest average AUC was chosen as the optimal 
biomarker combination. K-fold cross validation is a 
statistical analysis method used to test collected samples. 
The collected data samples were divided into k samples 
mutually exclusively. One sub-sample is left as validation 
data for the model test and the remaining k - 1 sub-sample 
were used as training data. Each time a sub-sample was 
used as validation data, k sub-samples are repeated k 
times during the cross validation process. Each k results 
from each step and component of this process were used 
to calculate an average to create a single evaluation assay 
used for the study (Kohavi 1995). Bootstrap estimates are 
able to evaluate the potential of a model only by using the 
training data. Within this method, the sample’s hold-out 
testing independence can be maintained (Amonkar et al. 
2009).
 Figure 1 shows an average AUC convergence graph 
based on a 5-fold cross validation. The value changed 
rapidly until it was repeated approximately 300 times. 
The average AUC stabilized after the 1000th 5-fold cross 
validation.
TABLE 2. Clinical samples for serum & urine biomarker testing
Serum Urine
Characteristics No. of patients Characteristics No. of patients
No. of patients studied
Benign Tumor
Ovarian Cancer
220
119
101
No. of patients studied
Benign Tumor
Ovarian Cancer
220
119
101
Figo Stage Figo Stage
Ⅰ
Ⅱ
Ⅲ
Ⅳ
34
15
37
15
Ⅰ
Ⅱ
Ⅲ
Ⅳ
26
9
54
12
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 RESULTS AND DISCUSSION
For assessment of urine and serum biomarker sample 
data, we used a logistic regression algorithm to calculate 
the AUC, sensitivity, specificity, distribution, accuracy, 
positive predictive value (PPV) and negative predictive 
value (NPV) using leave-one-out cross validation, without 
revealing the names of the biomarkers to avoid violation 
of patent laws. Table 3 shows the top 3 diagnostic 
performances of 2-urine-biomarker combinations and 
top 3 diagnostic performances of 2-serum-biomarker 
combinations (%).
 Urine biomarker combination with the best 
performance was the marker combination M9 and M8 
with an AUC of 89.89% and accuracy of 77.27%. Serum 
biomarker combination with the best performance was 
the combination M15 and M9 with an AUC of 92.40% 
and accuracy of 82.73%. 
 Figure 2(a) and 2(b) shows the ROC curve of a 
2-biomarker combination of urine and serum markers with 
good performance.
 Table 4 shows the top 3 diagnostic performances 
of 3-urine-biomarker combinations and top 3 diagnostic 
performances of 3-serum-biomarker combinations. The 
3-urine-biomarker combination with the best performance 
was M13, M9, and M8 with an AUC value of 90.22% and 
accuracy of 82.27%. The 3-serum-biomarker combination 
with the best performance was M15, M13, and M9 with 
an AUC value of 93.63% and accuracy of 83.64%. 
TABLE 3. Top 3 diagnostic performances of 2-urine & serum-biomarker combinations (%)
Urine Serum
 Markers M9,M8 M13,M9 M9,M6 Markers M15,M9 M13,M9 M1,M9
AUC 87.89 86.6 86.27 AUC 92.4 91.51 89.34
95% CI 85.78~92.14 80.09~91.11 80.52~90.06 95% CI 88.46~95.26 86.83~94.66 83.69~92.94
Sensitivity
Specificity
Accuracy
57.43
94.12
77.27
60.4
98.32
80.91
57.43
96.64
78.64
Sensitivity
Specificity
Accuracy
69.31
94.12
82.73
66.34
94.12
81.36
59.41
98.32
80.45
TABLE 4. Top 3 diagnostic performances of 3-urine&serum-biomarker combinations (%)
Urine Serum
 Markers M13,M9 
M8
M9,M7 
M8
M9,M6 
M8
Markers M15,M13 
M9
M7,M15 
M9
M6,M15 
M9
AUC 90.22 88.86 88.81 AUC 93.63 93.39 93.26
95% CI 86.41~94.74 84.06~93.03 84.06~92.99 95% CI 90.21~96.20 89.90~95.82 89.65~95.65
Sensitivity
Specificity
Accuracy
62.38
99.16
82.27
63.37
94.96
80.45
59.41
96.64
79.55
Sensitivity
Specificity
Accuracy
78.28
93.28
83.64
70.6
95.8
84.09
70.3
94.96
83.64
FIGURE 1. Average AUC convergence graph
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 Figure 2(c) and 2(d) shows the ROC curves of the 
3-urine-and-serum-biomarker combinations with good 
performance.
 Table 5 shows the top 3 diagnostic performances of 
the 4-urine-biomarker combinations and top 5 diagnostic 
performances of the 4-serum-biomarker combinations. The 
4-urine-biomarker combination with the best performance 
was M13, M9, M6, and M8 with an AUC of 92.43% and 
accuracy of 82.73%. The 4-serum-biomarker combination 
with the best performance was M6, M15, M13, and M9 
with an AUC of 94.63% and accuracy of 85.91%. 
 Figure 2(e) and 2(f) shows the ROC curves of the 
43-urine-and-serum-biomarker combinations with good 
performance.
 CONCLUSION
In this study, using serum and urine biomarker data, the 
optimal combination of 2, 3, and 4 biomarkers was used 
to evaluate their performance. Using logistic regression 
analysis, the score of each biomarker combination was 
calculated and 5-fold cross validation was repeated 1000 
times to obtain the average AUC value. By choosing those 
with high average values, the AUC, sensitivity with 95% 
of specificity and accuracy were analyzed.
 The performance of 2, 3 and 4 urine biomarkers were 
analyzed and those with the best performance included 
M9 and M8 at 87.89%; M13, M9, and M8 at 90.22%; 
and M13, M9, M6 and M8 at 92.43% for the AUC. This 
finding shows that using more biomarkers could lead to 
better performance.
 The performance of 2, 3 and 4 serum biomarkers was 
analyzed and those with the best performance were M15 
and M9 at 92.4%; M15, M13, and M9 at 93.63%; and M13, 
M6, M15 and M9 at 94.63% for the AUC. This finding also 
showed that using more biomarker combinations could 
lead to better performance. On comparing the effectiveness 
of urine and serum biomarkers, serum biomarkers were 
TABLE 5. Top 3 diagnostic performances of 4-urine&serum-biomarker combinations (%)
Urine Serum
 Markers M13,M9 
M6,M8
M13,M9 
M7,M8
M13,M9 
M15,M8
Markers M6,M15 
M13,M9
M7,M15 
M13,M9
M4,M15 
M13,M9
AUC 92.43 91.56 91.47 AUC 94.63 94.37 94.26
95% CI 86.64~95.42 86.55~94.72 87.12~94.80 95% CI 91.10~96.65 90.41~96.60 90.65~96.44
Sensitivity
Specificity
Accuracy
62.38
1
82.73
64.36
99.16
83.18
65.35
97.48
82.73
Sensitivity
Specificity
Accuracy
77.23
93.28
85.91
75.25
93.28
85
72.28
93.28
83.64
FIGURE 2. Comparison of combinations of 2, 3, 4 urine and serum biomarkers
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found to yield more accurate results than urine biomarkers, 
albeit to a small degree. However, normally, getting and 
handling urine sample are much easier and less expensive 
than serum sample. With this result, using urine sample 
rather than serum sample could be more recommendable 
for its practical issues even though it’s very tiny lower AUC 
values than the serum.
 In obtaining the optimal 4-biomarker combination, 
more time and cost were incurred. Therefore, further 
studies are needed to identify an optimal algorithm to 
obtain the most accurate biomarker combination in a cost- 
and time-efficient manner. The results of this study may 
aid in the early diagnosis of ovarian cancer. 
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